These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 32781522)
41. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Studer RK; Aboka AM; Gilbertson LG; Georgescu H; Sowa G; Vo N; Kang JD Spine (Phila Pa 1976); 2007 Dec; 32(25):2827-33. PubMed ID: 18246004 [TBL] [Abstract][Full Text] [Related]
42. Anisomycin activates p38 MAP kinase to induce LTD in mouse primary visual cortex. Xiong W; Kojic LZ; Zhang L; Prasad SS; Douglas R; Wang Y; Cynader MS Brain Res; 2006 Apr; 1085(1):68-76. PubMed ID: 16581040 [TBL] [Abstract][Full Text] [Related]
43. Cardioprotective effect of a combination of Rho-kinase inhibitor and p38 MAPK inhibitor on cardiovascular remodeling and oxidative stress in Dahl rats. Takeshima H; Kobayashi N; Koguchi W; Ishikawa M; Sugiyama F; Ishimitsu T J Atheroscler Thromb; 2012; 19(4):326-36. PubMed ID: 22166971 [TBL] [Abstract][Full Text] [Related]
44. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Gibbs KL; Kalmar B; Rhymes ER; Fellows AD; Ahmed M; Whiting P; Davies CH; Greensmith L; Schiavo G Cell Death Dis; 2018 May; 9(6):596. PubMed ID: 29789529 [TBL] [Abstract][Full Text] [Related]
45. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. Das S; Tosaki A; Bagchi D; Maulik N; Das DK J Pharmacol Exp Ther; 2006 Jun; 317(3):980-8. PubMed ID: 16525036 [TBL] [Abstract][Full Text] [Related]
46. Vitegnoside Mitigates Neuronal Injury, Mitochondrial Apoptosis, and Inflammation in an Alzheimer's Disease Cell Model via the p38 MAPK/JNK Pathway. Wang Q; Jiang H; Wang L; Yi H; Li Z; Liu R J Alzheimers Dis; 2019; 72(1):199-214. PubMed ID: 31561371 [TBL] [Abstract][Full Text] [Related]
47. The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells. Bagley MC; Dwyer JE; Baashen M; Dix MC; Murziani PG; Rokicki MJ; Kipling D; Davis T Org Biomol Chem; 2016 Jan; 14(3):947-56. PubMed ID: 26611938 [TBL] [Abstract][Full Text] [Related]
48. p38 MAPK-dependent alphaB-crystallin phosphorylation in Alzheimer's disease-like pathology in OXYS rats. Muraleva NA; Kolosova NG; Stefanova NA Exp Gerontol; 2019 May; 119():45-52. PubMed ID: 30664924 [TBL] [Abstract][Full Text] [Related]
49. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752 [TBL] [Abstract][Full Text] [Related]
50. Differential roles of ERK, JNK and p38 MAPK in pain-related spatial and temporal enhancement of synaptic responses in the hippocampal formation of rats: multi-electrode array recordings. Liu MG; Wang RR; Chen XF; Zhang FK; Cui XY; Chen J Brain Res; 2011 Mar; 1382():57-69. PubMed ID: 21284942 [TBL] [Abstract][Full Text] [Related]
51. A role for COX-2 and p38 mitogen activated protein kinase in long-term depression in the rat dentate gyrus in vitro. Murray HJ; O'Connor JJ Neuropharmacology; 2003 Mar; 44(3):374-80. PubMed ID: 12604095 [TBL] [Abstract][Full Text] [Related]
53. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard. Yego EC; Dillman JF Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002 [TBL] [Abstract][Full Text] [Related]
54. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice. Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812 [TBL] [Abstract][Full Text] [Related]
55. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. Li Y; Liu L; Barger SW; Griffin WS J Neurosci; 2003 Mar; 23(5):1605-11. PubMed ID: 12629164 [TBL] [Abstract][Full Text] [Related]
56. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease. Pinsetta FR; Taft CA; de Paula da Silva CH J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842 [TBL] [Abstract][Full Text] [Related]
57. Capsaicin Attenuates Amyloid-β-Induced Synapse Loss and Cognitive Impairments in Mice. Chen L; Huang Z; Du Y; Fu M; Han H; Wang Y; Dong Z J Alzheimers Dis; 2017; 59(2):683-694. PubMed ID: 28671132 [TBL] [Abstract][Full Text] [Related]
58. Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species. Fehr S; Unger A; Schaeffeler E; Herrmann S; Laufer S; Schwab M; Albrecht W Cell Physiol Biochem; 2015; 36(6):2237-49. PubMed ID: 26279429 [TBL] [Abstract][Full Text] [Related]
59. Ferrostatin-1 mitigates cognitive impairment of epileptic rats by inhibiting P38 MAPK activation. Ye Q; Zeng C; Luo C; Wu Y Epilepsy Behav; 2020 Feb; 103(Pt A):106670. PubMed ID: 31864943 [TBL] [Abstract][Full Text] [Related]
60. p38 MAPK: a potential target of chronic pain. Lin X; Wang M; Zhang J; Xu R Curr Med Chem; 2014; 21(38):4405-18. PubMed ID: 25245374 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]